Camelia Doina VRABIE, Manole COJOCARU, Inimioara Mihaela COJOCARU, Isabela SILOSI

Accelerated atherosclerosis in autoimmune rheumatic diseases

Ateroskleroz artan bir şekilde dammar sisteminin immune system aracılı bir oluşumu olarak algılanmaktadır. Otoantikorlar, otoantijenler, yangı artırıcı sitokinler ve enfeksiyöz etkenler bu oluşumda rol alabilir. Ototimmunite bağlantılı kalp-damar hastalıkları ve damar sertliği önemli klinik sorunlardır. Otoimmun romatizmal hastalıklarda hızlanmış damar sertliği gelişmesinin nedeni açık değildir. Bazı otoimmunite ilişkili kalp-damar sorunları damar sertliğinden ziyade tromboz ile ilişkilidir. Artan riskin mekanizmaları net olarak açıklanmamakla birlikte, geleneksel olan ve olmayan risk faktörlerinin - yangı da içlerinde olarak – bir kombinasyonu önemli gözükmektedir. Otoimmun romatizmal hastalıkların hızlanmış damar sertleşmesi ve belirtileri ile birlikte olup olmadığı konusunda yeni araştırmalara gereksinim vardır.

Otoimmun romatizmal hastalıklarda hızlanmış damar sertleşmesi

Atherosclerosis is increasingly considered an immune system-mediated process of the vascular system. Autoantibodies, autoantigens, pro-inflammatory cytokines and infectious agents play a role in that process. Autoimmunity-related cardiovascular disease and atherosclerosis are important clinical problems. The reason for accelerated atherosclerosis in patients with autoimmune rheumatic diseases remains unclear. Some cases of autoimmunity-related cardiovascular disease may be more related to thrombosis than atherosclerosis. Although, mechanisms causing the increased risk are not precisely clarified, a combination of traditional and nontraditional risk factors, including inflammation appears to be of importance. Further studies are needed to determine whether these autoimmune rheumatic diseases are also associated with accelerated atherosclerosis and its manifestations.

PDF

___

1. Zinger H, Sherer Y, Shoenfeld Y. Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings. Clin Rev Allergy Immunol 2009;37:20-8
2. Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004;22:361-403
3. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;109(Suppl I): II-2-II-10
4. Jara LJ, Medina G, Vera-Lastra G, Amigo MC. Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases. Autoimmun Rev 2006;5:195-201.
5. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-3347.
6. Shoenfeld Y, Sherer Y, Haratz D. Atherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol 2001;22:293-295.
7. Goodson N. Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 2002;14:115-20
8. Dessein PH, Tobias M, Veller MG. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2006;33:2425-2432
9. Van Doornum S, Mc Coll G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862-873.
10. Maradit–Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722-32.
11. del Rincon I, Williams K, Stern MP, Freeman GL, O’Leary DH, Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003;48:1833-40.
12. Gerli R, Schillaci G, Giordano A, et al. CD4+CD28-T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004;109:2744-8.
13. Gerli R, Bocci EB, Sherer Y, Vaudo G, Moscatelli S, Shoenfeld Y. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:724-5.
14. Nakken B, Szodoray P. Accelerated atherosclerosis in rheumatoid arthritis: rational for mannose-binding lectins? J Rheumatol 2010;37:482-4.
15. Frostegand J. SLE, atherosclerosis and cardiovascular disease. J Intern Med 2005;257:485-95
16. Szekanecz Z, Shoenfeld Y. Lupus and cardiovascular disease: the facts. Lupus 2006;15(11_suppl): 3-10.
17. Svenungsson E, Jensen-Urstad K, Heimburger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001;104:1887-93
18. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus . N Engl J Med 2003;349:2399-406
19. Jara LJ, Medina G, Vera-Lastra O, Shoenfeld Y. Atherosclerosis and antiphospholipid syndrome. Clin Rev Allergy Immunol 2003;25:79-87.
20. Spronk PE, Overbosch EH, Schut NH. Severe atherosclerotic changes, including aortic occlusion, associated with hyperhomocysteinaemia and antiphospholipid antibodies. Ann Rheum Dis 2001;60:699-701.
21. Ames PR, Margarita A, Sokoll KB, Weston M, Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 2005;64:315-7.
22. Jimenez S, Garcia-Criado MA, Tassies D, et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 2005;44:756-61.
23. Matucci Cerinic M, Fiori G, Grenbaum E, Shoenfeld Y. Macrovascular disease in systemic sclerosis. In: Furst D, Clements P, eds. Systemic sclerosis. Baltimore, Md: Lippincott Williams and Wilkins; 2003; 241.
24. Szucs G, Timar O, Szekanecz Z, et al. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis-relevance for prevention of vascular complications. Rheumatology 2007;46:759-62.
25. Alan S, Ulgen MS, Akdeniz S, Alan B, Toprak N. Intima-media thickness and arterial distensibility in Behçet’s disease. Angiology 2004;55:413-9.
26. Cantu C, Pineda C, Barinagarrementeria F, Salgado P, Gurza A, Paola de P, Espinosa R, Martinez-Lavin M. Noninvasive cerebrovascular assessment of Takayasu arteritis. Stroke 2000;31:2197-202.
27. de Leeuw K, Sanders JS, Stegeman C, Smit A, Kallenberg CG, Bijl M. Accelerated atherosclerosis in patients with Wegener’s granulomatosis. Ann Rheum Dis 2005;64:753-9.
28. Bacon PA. Endothelial cell dysfunction in systemic vasculitis: New developments and therapeutic prospects. Curr Opin Rheumatol 2005;17:49-55.